Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Royal Prima TbkISX:PRIM -1.82%73 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates ISX:PRIM with a GF Score™ of 73/100 and a GF Value™ of Rp82.10 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 526 Healthcare Providers & Services companies, PT Royal Prima Tbk ranks worse than 190113.88% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of PT Royal Prima Tbk was 124.70% per year. The lowest was -5.60% per year. And the median was 37.30% per year.
PT Royal Prima Tbk (ISX:PRIM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
PT Royal Prima Tbk 3-Year EBITDA Growth Rate Related Terms
ISX:PRIM vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, PT Royal Prima Tbk's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Royal Prima Tbk 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Royal Prima Tbk's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where PT Royal Prima Tbk's 3-Year EBITDA Growth Rate falls into.
PT Royal Prima Tbk 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
PT Royal Prima Tbk (ISX:PRIM) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PT Royal Prima Tbk and its competitors. According to the industry distribution chart, PT Royal Prima Tbk ranks #999999 out of 526 companies in the Healthcare Providers & Services industry.
Is PT Royal Prima Tbk's 3-Year EBITDA Growth Rate too high?
PT Royal Prima Tbk's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, PT Royal Prima Tbk ranks #999999 out of 526 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PT Royal Prima Tbk has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Royal Prima Tbk's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Royal Prima Tbk ranks #999999 out of 526 companies for 3-Year EBITDA Growth Rate. This places PT Royal Prima Tbk in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PT Royal Prima Tbk and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Royal Prima Tbk's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Royal Prima Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Royal Prima Tbk (ISX:PRIM) is currently considered Significantly Overvalued. The stock's GF Value™ is Rp82.10, compared to a current price of Rp108.00 — trading 31.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. PT Royal Prima Tbk's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PT Royal Prima Tbk (ISX:PRIM), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Royal Prima Tbk (ISX:PRIM) Overvalued in 2026?
Based on GuruFocus' analysis, PT Royal Prima Tbk stock appears to be overvalued.
The current stock price of Rp108.00 is trading 31.5% above its estimated GF Value™ of Rp82.10.
GuruFocus considers PT Royal Prima Tbk to be Significantly Overvalued.
Key valuation signals for ISX:PRIM:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: Rp82.10 vs. price of Rp108.00 (31.5% above fair value)
No single metric tells the full story. See the ISX:PRIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Royal Prima Tbk is engaged in health services which consist of the provision of hospital services, polyclinics, hall treatment, maternity hospital, and specialist hospital. It has three geographic segments: RSU Royal Prima, RS Royal Prima Jambi, and Rumah Sakit Marelan. The company generates the majority of its revenue from RSU Royal Prima segment. The company generates revenue from Drugs and medical supplies, doctors' and nurses' fees, Hospital facilities, Room services, and Others.
73GF Score
Get the complete analysis for ISX:PRIM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PRIM has been successfully added to your 
